Skip to content
Head to head

Tilray Brands vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: TLRY · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

TLRY -81.7%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
TLRYTAK
Snapshot
Sector----
Last price1.8921.77
Change today-8.70%+1.68%
1-year return-79.0%+57.5%
Market cap$279.32M$69.76B
52-week range1.87 – 15.7013.92 – 22.07
Valuation
P/E (TTM)-1.34311.00
P/E percentile, own 5-yr range48th100th
P/B0.171.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-1.09-0.30
Net profit (TTM)$-161.09M$-970.94M
Revenue (TTM)$963.10M$4.69T
Provider revenue period date2026-08-302026-09-29
Revenue growth (YoY)+22.7%+6.7%
Gross margin29.1%65.8%
Operating margin-6.3%14.3%
Net margin-17.1%0.9%
Free cash flow (TTM)$-118.82M$433.95B
Provider cash-flow period date2026-08-302026-09-29
Ownership & sentiment
Institutional ownership10.9%51.3%
Insider activity (12mo)34 buy / 16 sell19 buy / 31 sell
Short interest (% of float)13.2%0.1%
Analyst consensus50% buy / 50% hold (6)100% buy (1)
Analyst price target$7 (+257%)$50 (+132%)
StockVane view
StockVane Quant RatingE (1)C (90)
Company
Employees3,59547,029
Founded20181781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.